OPKO Health Reports Fourth Quarter 2022 Business Highlights and Financial Results
<!-- Name:DistributionId Value:8755815 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
OPKO
OPKO Health Reports 2022 Second Quarter Business Highlights and Financial Results
MIAMI, Aug. 04, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2022. Business…
OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology…
Dr. Elias Zerhouni, ModeX Chairman, former President of Global R&D at Sanofi and former NIH Director, named President and Vice Chairman of OPKODr. Gary Nabel, ModeX President and CEO,…
OPKO Health Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat…
MIAMI, Dec. 23, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces preliminary topline results from its Phase 2 trial with RAYALDEE® to treat mild-to-moderate COVID-19.…
Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License…
NEW YORK and MIAMI, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has…
OPKO Health Completes Enrollment in Phase 2 Trial Evaluating RAYALDEE as a Treatment…
MIAMI, Aug. 30, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces the completion of enrollment in its Phase 2 trial with RAYALDEE® as a treatment for mild-to-moderate…